Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of salvianolic acid a in the preparation of medicines for the treatment of pneumonia caused by methicillin-resistant Staphylococcus aureus

A staphylococcus infection, methicillin-resistant technology, applied in the field of medicine, can solve problems such as treatment failure

Active Publication Date: 2021-05-07
JILIN AGRICULTURAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The current drugs for the treatment of Staphylococcus aureus pneumonia usually use baxacillin and cloxacillin. Severe MRSA infection can be treated with the glycopeptide antibiotic vancomycin, but due to the emergence of vancomycin-resistant MRSA bacteria, it often leads to treatment fail

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of salvianolic acid a in the preparation of medicines for the treatment of pneumonia caused by methicillin-resistant Staphylococcus aureus
  • Application of salvianolic acid a in the preparation of medicines for the treatment of pneumonia caused by methicillin-resistant Staphylococcus aureus
  • Application of salvianolic acid a in the preparation of medicines for the treatment of pneumonia caused by methicillin-resistant Staphylococcus aureus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1, the inhibitory effect of salvianolic acid A on Staphylococcus aureus virulence factor SrtA

[0026] Inoculate Escherichia coli BL21, an expression strain containing the pET28a-SrtA vector, into LB medium, shake at 200 rpm overnight at 37°C. On the next day, re-inoculate into LB medium with Kanna resistance at a ratio of 1:100, culture at 37°C, 200rpm to OD 600 Up to 0.6-0.8. Take 1 mL of bacterial liquid as the pre-induction control. For the remaining 30 min on ice, IPTG with a final concentration of 1 mM was added to induce overnight at 16°C and 180 rpm. On the next day, 1 mL of the bacterial liquid was taken as a post-induction control, and the bacterial cells were collected by centrifugation (4000 rpm, 30 min). The collected bacterial cells were resuspended with protein buffer, ultrasonically disrupted by using a sonicator, and the crushed supernatant and precipitate were collected by a centrifuge (12000 rpm, 1 h). Finally, the expression of protein...

Embodiment 2

[0029] Embodiment 2, the influence of salvianolic acid A on the growth of Staphylococcus aureus USA300

[0030] In order to further confirm that salvianolic acid A has no effect on the growth of Staphylococcus aureus USA300, the growth of Staphylococcus aureus USA300 in the presence of 256 μg / mL salvianolic acid A was measured. Staphylococcus aureus USA300 cultured overnight was added to sterile BHI broth containing or not containing 256 μg / mL of traditional Chinese medicine monomer at a ratio of 1:100, and grown at 37°C for 24 hours with shaking. The DMSO group was used as a control. The absorbance at 600 nm was measured at different time intervals using a UV spectrophotometer, and the growth curve was drawn. The results are attached figure 2 shown. Even though the dose of salvianolic acid A is its IC 50 40 times that of S. aureus, the growth rate of S. aureus was still similar to that of WT. The results showed that salvianolic acid A could be used as a potential antivi...

Embodiment 3

[0031] Example 3, Salvianolic acid A inhibits Staphylococcus aureus from invading A549 cells

[0032] Human lung epithelial cells A549 were suspended in DMEM / high glucose medium (containing 10% fetal bovine serum), and then cultured 3×10 5 Cells were inoculated into 24-well cell culture plates (cover slips with a diameter of 12 mm), placed in a cell culture incubator at 37 ° C, 5% CO2 Incubate overnight. The Staphylococcus aureus cultured overnight was inoculated into the medium containing salvianolic acid A at a final concentration of 64 μg / mL and 128 μg / mL at a ratio of 1:100, and the culture was continued until the absorbance was OD 600nm = 1.0 for later use. Take out 1mL Staphylococcus aureus suspension from each group (absorbance is OD 600nm =1.0), added to the corresponding cells in the 24-well cell culture plate, with 3 replicates in each group, at 37°C, 5% CO 2 Incubate for 60 minutes under conditions. Each well was washed 3 times with PBS, then 1 mL of DMEM / high g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of salvianolic acid A in the preparation of medicines for treating Staphylococcus aureus infectious diseases. Specifically, the present invention discloses the application of salvianolic acid A in the treatment of Staphylococcus aureus, especially methicillin-resistant Staphylococcus aureus, alone or in combination with antibiotics. The purpose of the present invention is to introduce salvianolic acid into the treatment of Staphylococcus aureus infection, by using salvianolic acid A to inhibit the important virulence factor Sortase A, significantly reduce the pathogenicity of Staphylococcus aureus, and contribute to the body's immune system The removal of germs. The present invention also clarifies the molecular mechanism of salvianolic acid A inhibiting Staphylococcus aureus Sortase A, provides a reliable basis for salvianolic acid A to treat Staphylococcus aureus infection, and provides an important precursor compound for the development of new therapeutic drugs. It lays a certain foundation for the development of similar traditional Chinese medicines. Compared with the treatment with antibiotics, the treatment with salvianolic acid A has the characteristics of no drug resistance and high cure rate.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of salvianolic acid A in the preparation of a drug for treating methicillin-resistant Staphylococcus aureus infectious pneumonia. Background technique [0002] Staphylococcus aureus pneumonia is a disease caused by Staphylococcus aureus infection. In recent years, due to the widespread use of antibacterial drugs, bacteria have emerged multi-drug resistance, making the treatment of bacterial pneumonia face the situation that there is no cure. At present, clinically, Staphylococcus aureus, especially methicillin-resistant Staphylococcus aureus (MRSA), has become an important pathogenic bacteria of nosocomial pulmonary infection, and the pneumonia caused by it is relatively serious and has a high incidence in the world. It is an important cause of death in children, the elderly and immunocompromised patients. The current drugs for the treatment of Staphylococcus a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/216A61P31/04A61P11/00
CPCA61K31/216A61P11/00A61P31/04
Inventor 向华马红霞曲桂娟王大成王铁东王琳牡丹
Owner JILIN AGRICULTURAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com